AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
Migraine affects 1 in 7 people globally, significantly impacting quality of life and economic productivity. Despite its prevalence, limited awareness leads to misdiagnosis, inadequate treatment, and stigmatization. AI can enhance migraine management through improved diagnosis, prediction, and personalized education. Th
| Condition(s) | Migraine |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Migraine affects 1 in 7 people globally, significantly impacting quality of life and economic productivity. Despite its prevalence, limited awareness leads to misdiagnosis, inadequate treatment, and stigmatization. AI can enhance migraine management through improved diagnosis, prediction, and personalized education. The primary objective of this study is to determine if adding AI-assisted migraine education to standard education improves patients' understanding of their condition more effectively. |
| Who can participate | Inclusion Criteria: * aged between 18 and 65 years at the time of signing the informed consent * Newly diagnosis of migraine, confirmed through the medical chart * The participant must be capable of giving signed informed consent * Access to a laptop, computer, smartphone, or tablet Exclusion Criteria: * Insufficient knowledge of the protocol language (italian) * Patients with cognitive impairment and/or unable to use or access the AI-powered learning platform developed in this study. * Vulnerable participants (e.g. minors, participants incapable of judgment or participants under tutelage) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | Ente Ospedaliero Cantonale, Bellinzona |
| Locations | Lugano, Switzerland |
| Start date | 2024-09-01 |
| NCT ID | NCT06507150 |
| Official listing | https://clinicaltrials.gov/study/NCT06507150 |